Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study.

about

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study.

Item

http://www.wikidata.org/entity/Q52684522

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Depth and durability of respon ...... follow-up of a phase II study.

@en

Depth and durability of respon ...... follow-up of a phase II study.

@nl

type

Item

label

Depth and durability of respon ...... follow-up of a phase II study.

@en

Depth and durability of respon ...... follow-up of a phase II study.

@nl

prefLabel

Depth and durability of respon ...... follow-up of a phase II study.

@en

Depth and durability of respon ...... follow-up of a phase II study.

@nl

P1476

Depth and durability of respon ...... follow-up of a phase II study.

@en

P2093

Adrian Wiestner

http://www.w3.org/2001/XMLSchema#string

Carsten U Niemann

http://www.w3.org/2001/XMLSchema#string

Christian H Geisler

http://www.w3.org/2001/XMLSchema#string

Clare Sun

http://www.w3.org/2001/XMLSchema#string

Constance M Yuan

http://www.w3.org/2001/XMLSchema#string

Georg Aue

http://www.w3.org/2001/XMLSchema#string

Gerald E Marti

http://www.w3.org/2001/XMLSchema#string

Inhye E Ahn

http://www.w3.org/2001/XMLSchema#string

Irina Maric

http://www.w3.org/2001/XMLSchema#string

Janet Valdez

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia

P31

scholarly article

P356

10.1182/BLOOD-2017-12-820910

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29483101

http://www.w3.org/2001/XMLSchema#string

P932

5969380

http://www.w3.org/2001/XMLSchema#string